🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📢Meet the #iHF Social Media Team: Amina Marta Belmonte Matteo Casenghi David Duncker Emanuele Gallinoro, MD, PhD Pasquale Paolisso Hatem Soliman, FRCP, FEACVI, FASE, FHEA Prof. Izabella Uchmanowicz, RN, PhD,MBA,FESC, FHFA They’ll be sharing all the latest on #heartfailure care & our initiative🤳. Follow them & tag your updates with #ImprovingHeartFunction to

Emerging data suggests that one-size-fits-all troponin thresholds may miss the mark, especially in older adults. Read more in #EHJ. doi.org/10.1093/eurhea… #troponin #ischemic #cardiotwitter European Society of Cardiology Journals European Society of Cardiology

👉Pts with both AS and DM face challenges arising from the interaction between the 2 conditions. 🎯To investigate the effects of DM on the LV remodelling in AS patients, specifically focusing on the inflammatory response and oxidative stress. 👥 LV myocardial biopsies were

🎤Coming out of the #ImprovingHeartFunction session "Decompensated heart failure: indication and management of mechanical circulatory support" at #EuroPCR, Emanuele Gallinoro, MD, PhD asked Alexandre Mebazaa to comment on this very interactive session!

🎥Key insights from the #ImprovingHeartFunction session on refractory #heartfailure at #EuroPCR with Jozef Bartunek and Marta Belmonte

🥳Welcome to our New Associate Editors for #CardiovascularDiabetology - BMC ⭐️Dr. Idit Goldfracht, PhD Columbia University, New York City, USA Expertise: Tissue engineering, stem cells, cardiovascular disease, 3D printing, biomaterials, vascularized 3D tissues,

Proud of the amazing Teamwork by the entire Cardiology Team at #AziendaOspedalieraSantAndrea for the two Live Cases broadcast globally during #EuroPCR2025. This is a significant recognition of the teamwork, expertise, and innovation we bring to patient care every day!! 🔥🔥🔥

🚨We're thrilled to launch Cardiovascular Diabetology’s #KnowTheAuthors project - giving visibility to the brilliant minds behind the science! 🎥 First up: Maria Barranco-Altirriba presents key insights from her study on lipidomics and subclinical carotid atherosclerosis in T2D

GDMT and LVEF: from static measure to trajectories of change Journal Club review📷 shorturl.at/NVQeQ The clinical paradigm that relies on a static measurement of #LVEF to categorize and manage heart failure is increasingly recognized as reductive. There is a growing need

🎯To evaluate the impact of #SGLT2i on the risk of acute kidney injury (AKI) in #T2DM pts w/ severe #AS undergoing #TAVI. 👥 Multicenter Registry of consecutive pts stratified by the presence of CKD and anti-diabetic therapy (2021-2024). 🔥Our main findings were: - SGLT2i

💊#SGLT2i have emerged as potential cardioprotective agents, reducing cardiovascular mortality and improving #HF outcomes. 🎯Recent evidence suggests that SGLT2i exert anti-inflammatory effects, particularly through modulating the #inflammasome pathway. 🔥This review explores

🔥Proud to share that #CardiovascularDiabetology has achieved a new Impact Factor of 10.6 - its highest since 2009 - reinforcing its position among the leading journals in the Cardiovascular and Endocrinology & Metabolism fields. 🎯The journal now ranks 14th out of 230 in the

🚫Therapeutic impasse? Not anymore. Refractory heart failure is becoming a catalyst for change — in strategy, in collaboration, and in outcomes. 🔍 Emanuele Barbato & Alexandre Mebazaa dive into the power of combining pharmacological advances with device-based therapies in a

Prevention of #AFib with SGLT2-I across the spectrum of cardiovascular disorders: a meta-analysis of RCTs 📊 🔗 academic.oup.com/ehjcvp/advance… #EHJPharmacotherapy 💊 EHJ-CVP Editor-in-Chief 👔 European Society of Cardiology European Society of Cardiology Journals 📚

🎯To evaluate the relationship between CMR-imaging and pro-fibrotic/inflammatory serum biomarkers, to discriminate HFpEF from associated comorbid conditions. 👥Prospective cohort study of 35 obese participants (mean age 64 ± 8 yrs, 23% females), including: - 16 with T2DM - 13

Delayed GDMT up-titration in HFrEF? This new study selected by Prof. Izabella Uchmanowicz, RN, PhD,MBA,FESC, FHFA in the European Heart Journal combines a standardized 8-week protocol with home-based monitoring to overcome inertia & improve real-world outcomes. 🩺 A practical model for better heart failure care.

🫀 Cardiometabolic HFpEF phenotype (cmHFpEF) is rising fast, linked to obesity, hypertension, and chronic inflammation. 🔬 New insights reveal how metabolic stress, immune shifts, and epigenetic changes drive this condition. 🧬 Targeting metabolism, inflammation & chromatin